FDA Policy/General

FDA Hits Alar Pharmaceuticals Experimental Ketamine Promotion

FDA has cited Alar Pharmaceuticals over promotional materials for its investigational ketamine drug, ALA-3000, because they improperly portrayed the unapproved drug as safe and effective for treatment-resistant depression. A just-posted 8/21 untitled letter from CDER Office of Prescription Drug Promotion (OPDP) says the materials were on display at an Alar exhibit booth at the American Psychiatric Association’s 2026 Annual Meeting in San Francisco.

FDA’s letter notes that ALA-3000’s safety and effectiveness have not been established, and a company brochure appears to indicate that it had been studied only in Phase 1 clinical trials.

OPDP’s letter objects to several claims in Alar’s promotional materials, including statements that ALA-3000 had “no overall sedative, dissociative, psychosis-like side effects,” “no abuse signals,” and could potentially eliminate the at-least-two-hour period of on-site monitoring associated with ketamine therapies.

The agency says those claims were particularly concerning because ketamine is a Schedule III controlled substance associated with serious risks, including sedation, dissociation, respiratory depression, blood-pressure changes and abuse or misuse.

FDA also cites promotional language describing ALA-3000 as breaking “key barriers” in ketamine therapy and having a sustained-release profile. The promotional materials presented the investigational drug as safer or superior to other ketamine treatments without sufficient evidence to support those conclusions, it adds.

The letter asks Alar to take immediate action, including ceasing promotional communications that misbrand the drug. The company was given 15 working days after receiving the letter to respond, identify other promotional communications containing similar claims and explain how it plans to discontinue them.

OPDP posted images of the promotional materials here:

Promotional Material (PDF)
Promotional Material (PDF)

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome